Top-Rated StocksTop-RatedNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $38.82 -0.05 (-0.13%) As of 11:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xenon Pharmaceuticals Stock (NASDAQ:XENE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$38.71▼$39.2450-Day Range$30.30▼$38.8752-Week Range$26.74▼$46.00Volume46,795 shsAverage Volume885,104 shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice Target$53.20Consensus RatingBuy Company Overview Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreXENE MarketRank™: Xenon Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 674th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.47% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.47% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.12 News SentimentXenon Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Xenon Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest6 people have searched for XENE on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91.00 in company stock.Percentage Held by InsidersOnly 4.07% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Stock News HeadlinesDid Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?August 24, 2025 | finance.yahoo.comAn Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% UndervaluedAugust 21, 2025 | finance.yahoo.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 28 at 2:00 AM | Investors Alley (Ad)FY2025 Earnings Estimate for XENE Issued By Chardan CapitalAugust 18, 2025 | americanbankingnews.comTD Cowen Reaffirms Their Buy Rating on Xenon (XENE)August 13, 2025 | theglobeandmail.comXenon Completes Patient Recruitment for Phase 3 StudyAugust 13, 2025 | theglobeandmail.comXenon Pharmaceuticals price target lowered to $55 from $57 at RBC CapitalAugust 12, 2025 | msn.comXenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data ReleaseAugust 12, 2025 | seekingalpha.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $39.20 at the start of the year. Since then, XENE stock has decreased by 0.8% and is now trading at $38.87. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Monday, August, 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.04. Read the conference call transcript. Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' top institutional shareholders include Braidwell LP (4.68%), Commodore Capital LP (3.92%), Vestal Point Capital LP (2.59%) and Holocene Advisors LP (2.35%). Insiders that own company stock include Ian Mortimer, Dawn Svoronos, Gary Patou, Sherrington Robin, Steven Gannon, Simon N Pimstone, Christopher John Kenney and Sherry Aulin. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/11/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees210Year FoundedN/APrice Target and Rating Average Price Target for Xenon Pharmaceuticals$53.20 High Price Target$67.00 Low Price Target$43.00 Potential Upside/Downside+36.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$234.33 million Net MarginsN/A Pretax Margin-3,767.93% Return on Equity-38.50% Return on Assets-36.47% Debt Debt-to-Equity RatioN/A Current Ratio15.14 Quick Ratio15.14 Sales & Book Value Annual Sales$9.43 million Price / Sales317.84 Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book4.73Miscellaneous Outstanding Shares77,110,000Free Float73,968,000Market Cap$3.00 billion OptionableOptionable Beta1.16 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:XENE) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.